Intra-Cellular Therapies Future Growth
Future criteria checks 6/6
Intra-Cellular Therapies is forecast to grow earnings and revenue by 64.4% and 32.5% per annum respectively. EPS is expected to grow by 64.6% per annum. Return on equity is forecast to be 32.4% in 3 years.
Key information
64.4%
Earnings growth rate
64.6%
EPS growth rate
| Pharmaceuticals earnings growth | 23.7% |
| Revenue growth rate | 32.5% |
| Future return on equity | 32.4% |
| Analyst coverage | Good |
| Last updated | 05 Sep 2024 |
Recent future growth updates
Recent updates
Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Strong Position To Grow Its Business
Sep 22
Peaking Back In On Intra-Cellular Therapies
Sep 04Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
Aug 10With Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) It Looks Like You'll Get What You Pay For
Jul 27Intra-Cellular Brightens MDD Outlook With Caplyta Success
Jun 19Intra-Cellular: More Upside Possible Even After Positive MDD Treatment Data
Apr 16Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) P/S Is On The Mark
Apr 09We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow
Mar 17Intra-Cellular Therapies Is On Fire
Mar 11Intra-Cellular Therapies: Buoyant Caplyta Sales And Upcoming MDD Data Support Short-Term 'Buy'
Feb 11Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) Price Is Out Of Tune With Revenues
Dec 24We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow
Nov 11Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Can Afford To Invest In Growth
Aug 07Here's Why We're Not At All Concerned With Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Situation
May 09After Leaping 31% Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Are Not Flying Under The Radar
Apr 17We're Not Very Worried About Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Rate
Jan 31Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Good Position To Deliver On Growth Plans
Oct 25Intra-Cellular Therapies: What Lies Ahead
Sep 20Intra-Cellular cut to Neutral at Goldman on trends for antipsychotic drug
Aug 22Intra-Cellular Therapies GAAP EPS of -$0.92 misses by $0.15, revenue of $55.6M beats by $6.98M
Aug 09We're Hopeful That Intra-Cellular Therapies (NASDAQ:ITCI) Will Use Its Cash Wisely
Jul 09Intra-Cellular Therapies: A Dramatic Story
Jun 18Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Are In A Position To Invest In Growth
Apr 03Intra-Cellular: Not Participating In A Bear Market
Mar 31Intra-Cellular; Long-Term To Own With A Few FDA Approvals And Ability To Expand
Mar 08Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 1,360 | 400 | 417 | 488 | 14 |
| 12/31/2025 | 917 | 74 | 115 | 93 | 15 |
| 12/31/2024 | 667 | -64 | -59 | 8 | 15 |
| 6/30/2024 | 565 | -84 | -61 | -61 | N/A |
| 3/31/2024 | 514 | -111 | -99 | -98 | N/A |
| 12/31/2023 | 464 | -140 | -124 | -124 | N/A |
| 9/30/2023 | 420 | -155 | -162 | -161 | N/A |
| 6/30/2023 | 366 | -184 | -190 | -189 | N/A |
| 3/31/2023 | 311 | -228 | -248 | -247 | N/A |
| 12/31/2022 | 250 | -256 | -271 | -270 | N/A |
| 9/30/2022 | 188 | -298 | -305 | -304 | N/A |
| 6/30/2022 | 138 | -321 | -331 | -330 | N/A |
| 3/31/2022 | 103 | -304 | -296 | -295 | N/A |
| 12/31/2021 | 84 | -284 | -260 | -260 | N/A |
| 9/30/2021 | 71 | -259 | -255 | -255 | N/A |
| 6/30/2021 | 56 | -237 | -239 | -239 | N/A |
| 3/31/2021 | 38 | -232 | -227 | -227 | N/A |
| 12/31/2020 | 23 | -227 | -230 | -230 | N/A |
| 9/30/2020 | 10 | -207 | -196 | -197 | N/A |
| 6/30/2020 | 3 | -187 | -163 | -163 | N/A |
| 3/31/2020 | 1 | -160 | -144 | -144 | N/A |
| 12/31/2019 | 0 | -148 | -129 | -128 | N/A |
| 9/30/2019 | N/A | -148 | -123 | -122 | N/A |
| 6/30/2019 | N/A | -155 | -122 | -121 | N/A |
| 3/31/2019 | N/A | -154 | -127 | -127 | N/A |
| 12/31/2018 | N/A | -155 | -119 | -118 | N/A |
| 9/30/2018 | 0 | -145 | -115 | -114 | N/A |
| 6/30/2018 | 0 | -126 | -101 | -100 | N/A |
| 3/31/2018 | 0 | -106 | N/A | -91 | N/A |
| 12/31/2017 | 0 | -98 | N/A | -80 | N/A |
| 9/30/2017 | 0 | -95 | N/A | -84 | N/A |
| 6/30/2017 | 0 | -102 | N/A | -99 | N/A |
| 3/31/2017 | 0 | -116 | N/A | -88 | N/A |
| 12/31/2016 | 0 | -116 | N/A | -91 | N/A |
| 9/30/2016 | 0 | -118 | N/A | -98 | N/A |
| 6/30/2016 | 0 | -120 | N/A | -89 | N/A |
| 3/31/2016 | 0 | -110 | N/A | -106 | N/A |
| 12/31/2015 | 0 | -105 | N/A | -102 | N/A |
| 9/30/2015 | 0 | -91 | N/A | -73 | N/A |
| 6/30/2015 | 0 | -65 | N/A | -57 | N/A |
| 3/31/2015 | 0 | -48 | N/A | -32 | N/A |
| 12/31/2014 | 1 | -31 | N/A | -23 | N/A |
| 9/30/2014 | 1 | -24 | N/A | -25 | N/A |
| 6/30/2014 | 2 | -22 | N/A | -26 | N/A |
| 3/31/2014 | 2 | -26 | N/A | -27 | N/A |
| 12/31/2013 | 3 | -27 | N/A | -23 | N/A |
| 9/30/2013 | 3 | -20 | N/A | -18 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ITCI is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.5%).
Earnings vs Market: ITCI is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ITCI is expected to become profitable in the next 3 years.
Revenue vs Market: ITCI's revenue (32.5% per year) is forecast to grow faster than the US market (8.8% per year).
High Growth Revenue: ITCI's revenue (32.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ITCI's Return on Equity is forecast to be high in 3 years time (32.4%)